{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:40:55Z","timestamp":1715946055103},"reference-count":163,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharm. Pat. Anal."],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.4155\/ppa.14.18","type":"journal-article","created":{"date-parts":[[2014,7,7]],"date-time":"2014-07-07T11:28:21Z","timestamp":1404732501000},"page":"261-277","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Recent Advances in Antimultiple Myeloma Drug Development"],"prefix":"10.1080","volume":"3","author":[{"given":"Nuozhou","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences Computational Chemical Genomics Screening Center School of Pharmacy & Drug Discovery Institute University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Bartlow","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences Computational Chemical Genomics Screening Center School of Pharmacy & Drug Discovery Institute University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences Computational Chemical Genomics Screening Center School of Pharmacy & Drug Discovery Institute University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Qun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences Computational Chemical Genomics Screening Center School of Pharmacy & Drug Discovery Institute University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"},{"name":"Department of Computational & System Biology & Department of Structural Biology University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,7,7]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0949-x"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq370"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.2114"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2005.05.001"},{"issue":"9686","key":"e_1_3_2_7_1","first-page":"25","article-title":"Multiple myeloma \u2013 2009","volume":"374","author":"Raab MS","year":"2009","unstructured":"Raab MS Podar K Breitkreutz I Richardson PG Anderson KC . Multiple myeloma \u2013 2009. Lancet374 (9686), 25 (2009).","journal-title":"Lancet"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070209-175325"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054494"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-270140"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0294"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.350"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03060906"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-5-18"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1240901"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.v13i5.106"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.06.018"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620713480155"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-27"},{"key":"e_1_3_2_22_1","unstructured":"US FDA Approval for Lenalidomide. National Cancer Institute. www.cancer.gov\/cancertopics\/druginfo\/fda-lenalidomide"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.774393"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480501200204"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.11.1921"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/157496"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.12.026"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1760"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc952"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109068200"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.259"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1670"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04107"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01705.x"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0102"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2921"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00027.2001"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-4-397"},{"issue":"1","key":"e_1_3_2_40_1","first-page":"65","article-title":"Tumor necrosis factor is a survival and proliferation factor for human myeloma cells","volume":"10","author":"M Jourdan KT","year":"1999","unstructured":"M Jourdan KT Legouffe E Brochier J Rossi JF Klein B . Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur. Cytokine Netw.10 (1), 65\u201370 (1999).","journal-title":"Eur. Cytokine Netw."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605530"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1924-9"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S34498"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.38"},{"key":"e_1_3_2_45_1","unstructured":"Clinical Trials of Pomalidomide. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/results?protocolsearchid=7443751"},{"key":"e_1_3_2_46_1","unstructured":"Celgene Corporation: US7968569 (2011)."},{"key":"e_1_3_2_47_1","unstructured":"Clinical Trials of Lenalidomide. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/results?protocolsearchid=6467615"},{"key":"e_1_3_2_48_1","unstructured":"Novartis Pharma Gmbh: WO2006061199 (2006)."},{"key":"e_1_3_2_49_1","unstructured":"Dana-Farber Cancer Institute: WO2006060676 (2006)."},{"key":"e_1_3_2_50_1","unstructured":"Kosan Biosciences Inc.: WO2006118953 (2006)."},{"key":"e_1_3_2_51_1","unstructured":"CBR institute for biomedical research Inc.: WO2006116185 (2006)."},{"key":"e_1_3_2_52_1","unstructured":"Scios Inc.: US2006079461 (2006)."},{"key":"e_1_3_2_53_1","unstructured":"AB Science: WO2007026251 (2007)."},{"key":"e_1_3_2_54_1","unstructured":"Dana-Farber Cancer Institute: WO2007059078 (2007)"},{"key":"e_1_3_2_55_1","unstructured":"Millennium pharmaceuticals Inc.: EP1443927-B (2007)."},{"key":"e_1_3_2_56_1","unstructured":"Research Development Foundation: US20077196105 (2007)."},{"key":"e_1_3_2_57_1","unstructured":"Board of Regents the University of Texas System: US20077211252 (2007)."},{"key":"e_1_3_2_58_1","unstructured":"Prolexys Pharmaceuticals Inc.: WO2009002553 (2009)."},{"key":"e_1_3_2_59_1","unstructured":"Bayer schering pharma aktiengesellschaft: WO2010034414 (2010)."},{"key":"e_1_3_2_60_1","unstructured":"Cephalon Inc.: WO2010138141 (2010)."},{"key":"e_1_3_2_61_1","unstructured":"Novartis Vaccines and Diagnostics Inc.: EP1684805B (2010)."},{"key":"e_1_3_2_62_1","unstructured":"Novartis AG Novartis Pharma: US8012477 (2011)."},{"key":"e_1_3_2_63_1","unstructured":"SRI International: US8268807 (2012)."},{"key":"e_1_3_2_64_1","unstructured":"Ab Science: WO2012136732 (2012)."},{"key":"e_1_3_2_65_1","unstructured":"Telik Inc.: WO2012134915 (2012)."},{"key":"e_1_3_2_66_1","unstructured":"YM BioSciences Australia Pty Ltd: WO2012149602 (2012)."},{"key":"e_1_3_2_67_1","unstructured":"Xie X-Q Myint K Kurihara N Roodman D . WO2013022919 (2013)."},{"key":"e_1_3_2_68_1","unstructured":"Millennium Pharmaceuticals Inc.: US20130040979 (2013)."},{"key":"e_1_3_2_69_1","unstructured":"Xie X-Q Feng RT Yang P : US20130172388 (2013)."},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2597.2597"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4125"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3041225"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4179"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.47"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.37"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.9.3769-3781.2004"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.21.11675"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500080595"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12171"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2909"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1911"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.5.3922"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0004-2"},{"key":"e_1_3_2_84_1","article-title":"Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma","author":"Tsuchiya K","year":"2013","unstructured":"Tsuchiya K Asahina Y Matsuda S et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer (2013).","journal-title":"Cancer"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.403"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2043"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0264"},{"key":"e_1_3_2_88_1","unstructured":"Clinical Trials of Cabozantinib. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/view?cdrid=750134&version=HealthProfessional&protocolsearchid=6574837"},{"issue":"4","key":"e_1_3_2_89_1","first-page":"267","article-title":"Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis","volume":"4","author":"Shailubhai KDS","year":"2004","unstructured":"Shailubhai KDS , PickerD, KaurG, SausvilleEA, JacobGS. Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. J. Exp. Ther. Oncol.4 (4), 267\u2013279 (2004).","journal-title":"J. Exp. Ther. Oncol."},{"key":"e_1_3_2_90_1","unstructured":"Clinical trials of Atiprimod. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/view?cdrid=378176&version=HealthProfessional&protocolsearchid=12341971"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3913"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2129"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0957"},{"key":"e_1_3_2_94_1","unstructured":"Clinical Trials of TKI258. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/view?cdrid=665482&version=HealthProfessional&protocolsearchid=6706026"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009430"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq378"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1361"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70304-8"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_3_2_100_1","unstructured":"Carfilzomib. US FDA. www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm312945.htm"},{"key":"e_1_3_2_101_1","unstructured":"Onyx Pharmaceuticals Announces 2013 Updates and Reviews 2012 Achievements at J.P. Morgan Healthcare Conference. www.onyx.com\/view.cfm\/651\/onyx-pharmaceuticals-announces-2013-updates-and-reviews-2012-achievements-at-jp-morgan-healthcare-conference"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1213"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1950"},{"key":"e_1_3_2_104_1","unstructured":"Clinical trials of Carfilzomib. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/results?protocolsearchid=6526214"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-276626"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.4161\/auto.22185"},{"key":"e_1_3_2_107_1","unstructured":"Clinical trials of MLN9708. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/results?protocolsearchid=6786386"},{"key":"e_1_3_2_108_1","unstructured":"Gupta V Gonsalves WI Kumar SK . Novel proteasome inhibitors for multiple myeloma. www.targetedonc.com\/publications\/targeted-therapies-cancer\/2013\/june-2013\/novel-proteasome-inhibitors-for-multiple-myeloma\/1"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2766"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105601"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01558.x"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500472123"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1158"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.2219.bloodjournal8862219"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2734"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.026"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2377"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.09.004"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1309\/74R4TB90BUWH27JX"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.2119\/2006-00082.Stevenson"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.82"},{"issue":"3","key":"e_1_3_2_123_1","first-page":"610","article-title":"Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells","volume":"55","author":"Huang YW","year":"1995","unstructured":"Huang YW Richardson JA Vitetta ES . Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res.55 (3), 610\u2013616 (1995).","journal-title":"Cancer Res."},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-RW2013-091"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.882204"},{"issue":"1","key":"e_1_3_2_126_1","first-page":"184","article-title":"New insights into therapeutic targets in myeloma","volume":"2011","author":"Anderson KC","year":"2011","unstructured":"Anderson KC . New insights into therapeutic targets in myeloma. ASH Education Program Book2011 (1), 184\u2013190 (2011).","journal-title":"ASH Education Program Book"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.668883"},{"key":"e_1_3_2_128_1","first-page":"1623","article-title":"Profile of panobinostat and its potential for treatment in solid tumors: an update","volume":"6","author":"Anne M","year":"2013","unstructured":"Anne M Sammartino D Barginear MF Budman D . Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther.6, 1623\u20131624 (2013).","journal-title":"Onco Targets Ther."},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387365"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-222943"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-4666-8_6"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0763"},{"key":"e_1_3_2_133_1","unstructured":"Clinical trials of CC-223. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/results?protocolsearchid=9204255"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2640"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2006.02.026"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209337"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.001"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.175"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.109"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000034"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200360200"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.10"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055841"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173948"},{"key":"e_1_3_2_145_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0047"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C109.073627"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.888.888"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22033"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"issue":"5","key":"e_1_3_2_150_1","first-page":"453","article-title":"Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma","volume":"38","author":"Dun Xy Jiang H","year":"2009","unstructured":"Dun Xy Jiang H Hou J . Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma. Zhejiang Da Xue Xue Bao Ban.38 (5), 453\u2013458 (2009).","journal-title":"Zhejiang Da Xue Xue Bao Ban."},{"key":"e_1_3_2_151_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3879"},{"key":"e_1_3_2_152_1","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v3.i11.175"},{"key":"e_1_3_2_153_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081104"},{"key":"e_1_3_2_154_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047712"},{"key":"e_1_3_2_155_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191577"},{"key":"e_1_3_2_156_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-026112"},{"key":"e_1_3_2_157_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3562"},{"key":"e_1_3_2_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.11.015"},{"key":"e_1_3_2_159_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S36109"},{"key":"e_1_3_2_160_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2329"},{"key":"e_1_3_2_161_1","unstructured":"Clinical trial of MDX-1338. National Cancer Institute. www.cancer.gov\/clinicaltrials\/search\/results?protocolsearchid=12342358"},{"key":"e_1_3_2_162_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm3017464"},{"key":"e_1_3_2_163_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301212u"},{"key":"e_1_3_2_164_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-18"}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/ppa.14.18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:16:51Z","timestamp":1715944611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/ppa.14.18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":163,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.4155\/ppa.14.18"],"URL":"https:\/\/doi.org\/10.4155\/ppa.14.18","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"value":"2046-8954","type":"print"},{"value":"2046-8962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}